"Plurivax"-Project (Germany-Flanders) | ETB Project ETB-2013-46
ARTES Biotechnology , InstrAction (both Germany) and Q-Biologicals (Flanders, Belgium) build a three-party consortium for veterany applications. The three-years project is supported by the German Federal Ministry of Education and Research (BMBF) and by the Flanders (Belgium) agency for Innovation by Science and Technology (IWT).
ARTES Biotechnology testimony (PDF 150KB - October 2014)
Mologen AG (Germany) | ETB Project ETB-2009-81
The German Company Mologen AG received an ETB grant worth of 280.000€. The MIDGE®-project is being co-financed by the German Federal Ministry of Education and Research, as part of the EU's ETB initiative.
"The funding enables us to develop a further MIDGE-based vaccine product for a disease where an improved method of treatment has always been a major medical need", said Dr. Matthias Schroff, the Chief Executive Officer of MOLOGEN AG. "Within the new project we will be developing another modern DNA vaccine based on one of our key technologies to add to the vaccine against leishmaniasis in humans, which also received significant funding. As well as our expertise in combating cancer, we can now demonstrate our extensive ability in the development of DNA-based vaccines, and further expand our product pipeline."
Merus BV (The Netherlands) | ETB Project ETB-2009-118
The Dutch Company Merus BV received an ETB grant worth of € 0.67 million and financed via the "Life Science and Health" innovation program of SenterNovem (NL). This grant will enable Merus BV to develop innovative combinations of human therapeutic antibodies for the treatment of chronic inflammatory diseases.
Merus testimony (PDF - 64KB)